Atorvastatin, one of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, takes effect on regulating the level of cholesterol. It is beneficial in most of the cases like preventing stoke and coronary heart disease. Whereas it has been noted that atorvastatin can the breakdown of the tissues in the skeletal muscle thus leading to the kidney failure. Atorvastatin itself or in combination with other drugs can result in toxin effect on non-targeted organs. We should be cautious when prescribe this drug with thorough evaluation and careful consideration. Individualized or personalized usage of atorvastatin should be an evidence-based manner. Kidneys, as the outlet of the wastes from cellular metabolism, have been shown that function as the causing aspect of many other diseases due to the problem of its blood vessels narrowing which eventually results in piling up of the disease-causing wastes. The fact that the kidney is not able to function normally and extract the waste in the body like cholesterol means that the cholesterol in the body blood vessel will be deposited on the wall. Even atorvastatin functions as the killer of cholesterol, it still should be cautious when prescribe this drug to patients with reduced renal function, especially to those with chronic kidney disease, because of its nephritic toxic effect.
HMG-CoA Reductase Inhibitor, Atorvastatin, Cholesterol, Kidney, Toxicity
2. Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Luño J. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17:S231-S235.
3. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wenger NK. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51:1448-1454.
4. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Toto R. Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617-622.
5. Shepherd J, Kastelein JJ, Bittner VA, Carmena R, Deedwania PC, Breazna A, Wenger NK. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proceedings 2008; 83:870-879.
6. Trialists CT. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
7. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Mehlsen J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
8. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41:565-570.
9. Takagi H, Umemoto T. A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease. Int J Cardiol 2011; 152:242-244.
10. Lipitor – Statin & cholesterol drug could cause diabetes. (2016). Drug Watch. Retrieved 10 March 2016, from http://www.drugwatch.com/lipitor/ ("Lipitor – Statin & Cholesterol Drug Could Cause Diabetes", 2016).
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.